FEZF2 inhibits the growth of triple-negative breast cancer cells through EZH2/PD-L1 and enhances anti-tumor immunity in vivo

ConclusionOverexpression of FEZF2 inhibited the proliferation and enhanced the apoptosis of TNBC cells through EZH2/PD-L1 axis, as well as promoted anti-tumor immunity in vivo.

http://link.springer.com/10.1007/s13273-023-00368-9

Source: Molecular and Cellular Toxicology - June 19, 2023 Category: Cytology Source Type: research